GenVec, Inc.
(NASDAQ : GNVC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.73%126.630.6%$865.71m
ABBVAbbVie, Inc.
-0.52%92.532.1%$787.66m
MRKMerck & Co., Inc.
0.41%58.880.6%$737.02m
PFEPfizer Inc.
0.30%36.640.8%$736.77m
BMYBristol-Myers Squibb Company
-0.81%51.191.4%$515.80m
LLYEli Lilly and Company
-0.70%79.191.0%$286.20m
NVSNovartis AG Sponsored ADR
-1.28%77.990.2%$153.10m
AZNAstraZeneca PLC Sponsored ADR
-0.20%35.331.3%$150.46m
GSKGlaxoSmithKline plc Sponsored ADR
0.48%40.070.2%$140.55m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.60%47.380.1%$52.23m
SNYSanofi Sponsored ADR
-0.46%39.980.2%$51.14m
LCILannett Company, Inc.
1.20%16.8538.1%$10.95m
AKTXAkari Therapeutics Plc Sponsored ADR
-0.50%1.991.7%$0.18m
EPIXESSA Pharma Inc
-4.79%0.160.0%$0.02m

Company Profile

GenVec, Inc. is a clinical-stage gene delivery company, which engages in the development of therapeutics and vaccines. The firm designs, tests, and manufactures adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products include CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.